Pilot Safety and Proof of Principle Study of Intravenous DNase Therapy in SARS-CoV2 (COVID-19)

About this Study

Evaluation of IV DNase treatment of COVID-19 patients with evidence of early hypercoagulable disseminated intravascular coagulation to determine safety and efficacy in reducing levels of circulating cell-free DNA.

Sponsor Protocol ID:N/A
IRB Number:2020-0102
Pending Activation
Interventional
Phase 1
Eligibility Criteria
18 years old
Both Male and Female
No
No
No

Inclusion Criteria(1) ≥18 years of age; (2) inpatient status; (3) SARS-CoV-2 PCR test positive for infection; and (4) D-dimer > 500ng/mL FEU.

Exclusion Criteria

(1) Known hypersensitivity to dornase alpha; and (2) Pregnant or lactating.

(Protocol silent on dual enrollment).

Categories Click category to view its trials.
COVID-19 (Coronavirus)
Participating Locations
University Hospital - UMMC
Contact Information
Contact Name: Dr. Matthew Kutcher
Phone Number: 601-815-1312
Email: mkutcher@umc.edu
Principal Investigator:Kutcher, Matthew E, M.D., M.S.
How to participate in our Clinical Trials